These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

497 related items for PubMed ID: 32951601

  • 1. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
    Liu L, Zhang Z, Zhang G, Wang T, Ma Y, Guo W.
    J Transl Med; 2020 Sep 20; 18(1):357. PubMed ID: 32951601
    [Abstract] [Full Text] [Related]

  • 2. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, Ali-Fehmi R, Buekers T, Munkarah AR, Rattan R.
    Gynecol Oncol; 2016 Aug 20; 142(2):323-31. PubMed ID: 27282964
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.
    Chen M, Zeng J, Chen S, Li J, Wu H, Dong X, Lei Y, Zhi X, Yao L.
    Aging (Albany NY); 2020 Jun 08; 12(11):10896-10911. PubMed ID: 32516133
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Overexpression of long noncoding RNA HOXB-AS3 indicates an unfavorable prognosis and promotes tumorigenesis in epithelial ovarian cancer via Wnt/β-catenin signaling pathway.
    Zhuang XH, Liu Y, Li JL.
    Biosci Rep; 2019 Aug 30; 39(8):. PubMed ID: 31337688
    [Abstract] [Full Text] [Related]

  • 8. LDH-A inhibitors as remedies to enhance the anticancer effects of PARP inhibitors in ovarian cancer cells.
    Xiang J, Zhou L, He Y, Wu S.
    Aging (Albany NY); 2021 Dec 16; 13(24):25920-25930. PubMed ID: 34919531
    [Abstract] [Full Text] [Related]

  • 9. The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis.
    Yuan S, Xu Y, Yi T, Wang H.
    J Ethnopharmacol; 2022 Jan 30; 283():114706. PubMed ID: 34614446
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway.
    Hu W, Li M, Chen Y, Gu X.
    J Ovarian Res; 2021 Sep 17; 14(1):121. PubMed ID: 34535173
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
    Shi Y, Zhang J, Liu M, Huang Y, Yin L.
    J Cell Biochem; 2019 Jun 17; 120(6):10796-10811. PubMed ID: 30701575
    [Abstract] [Full Text] [Related]

  • 14. Oridonin represses epithelial-mesenchymal transition and angiogenesis of thyroid cancer via downregulating JAK2/STAT3 signaling.
    Liu W, Wang X, Wang L, Mei Y, Yun Y, Yao X, Chen Q, Zhou J, Kou B.
    Int J Med Sci; 2022 Jun 17; 19(6):965-974. PubMed ID: 35813296
    [Abstract] [Full Text] [Related]

  • 15. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
    Bai H, Li H, Li W, Gui T, Yang J, Cao D, Shen K.
    Oncotarget; 2015 Sep 22; 6(28):25520-32. PubMed ID: 26267321
    [Abstract] [Full Text] [Related]

  • 16. Pterostilbene suppresses gastric cancer proliferation and metastasis by inhibiting oncogenic JAK2/STAT3 signaling: In vitro and in vivo therapeutic intervention.
    He P, Li Y, Hu J, Deng B, Tan Z, Chen Y, Yu B, Dong W.
    Phytomedicine; 2024 Jun 22; 128():155316. PubMed ID: 38518635
    [Abstract] [Full Text] [Related]

  • 17. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S, Sun J, Cai B, Xi X, Yang L, Zhang Z, Feng Y, Sun Y.
    Tumour Biol; 2016 Jul 22; 37(7):9671-80. PubMed ID: 26801672
    [Abstract] [Full Text] [Related]

  • 18. LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model.
    Mehdi S, Macdonald E, Galpin K, Landry DA, Rodriguez G, Vanderhyden B, Bachvarov D.
    Int J Mol Sci; 2020 Jul 15; 21(14):. PubMed ID: 32679765
    [Abstract] [Full Text] [Related]

  • 19. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
    Li C, Ding H, Tian J, Wu L, Wang Y, Xing Y, Chen M.
    Cell Physiol Biochem; 2016 Jul 15; 39(3):1098-110. PubMed ID: 27562816
    [Abstract] [Full Text] [Related]

  • 20. Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.
    Liu YK, Jia YJ, Liu SH, Shi HJ, Ma J.
    Histol Histopathol; 2021 May 15; 36(5):535-545. PubMed ID: 33570156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.